Teva reorganizes

Share this article:

Teva is undergoing an overhaul as of July 1. Among the changes announced Monday were the creation of a Global Generics Medicines group, which will handle launch and commercialization of its generics portfolio, as well as its over-the-counter business. Former Actavis president Sigurder Olafsson will head this new division.

Additional changes include a new Corporate Development Strategy and Innovation Group, and a new Global Corporate Marketing Excellence and Communications Group.

Teva, which recently found out it will soon navigate a world with generic Copaxone medications, has been facing a series of challenges, including a tumultuous leadership period which capped 2013. The company said in a statement that these changes “are another key step in Teva's strategic direction to create a less complex, integrated company.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.